Margin protection offsets a slower top line
- The RISE strategy continues the turnaround, but 2026 revenue guidance has fallen to around 4 percent.
- Orthopaedics remains the largest unit, with 2025 revenue of $2,437 million.
- Management raised the efficiency savings target to $200 million, protecting profitability.
- The expected $60 million tariff headwind is now broadly neutral net of refunds for 2026.
- New operational risks include CATALYSTEM deployment delays and SANTYL prior authorization friction.
Efficiency saves a weak top line
Smith & Nephew is a medical device turnaround. The 12-Point Plan improved margins and cash flow. The new RISE strategy is the next phase, aiming to reach more patients, fund more innovation, and run the business through the Ortho360 operating model.
The bull case focuses on operational efficiency and new products. Management recently raised 2026 efficiency savings targets to $200 million, protecting margins despite top-line softness. The FDA also approved the TESSA spatial surgery platform, giving a new catalyst for Sports Medicine. Furthermore, the previously expected $60 million tariff headwind is now broadly neutral net of refunds.
The bear case centers on a slower top line. Management reduced 2026 revenue guidance to around 4 percent after a weak second quarter. U.S. Hips suffered from CATALYSTEM set deployment delays, and the wound care business faces new prior authorization friction for SANTYL. The CMS skin substitute reimbursement change is also tracking toward the upper end of the $20 million to $40 million profit hit.
The core test remains the same. U.S. Knees growth is soft as the company waits for the LANDMARK system launch in the second half of 2026. The stock needs proof that LANDMARK and TESSA can successfully re-accelerate growth.
Three ways to sell into care
Smith & Nephew makes money by selling devices and supplies to hospitals, surgery centers, doctors, and wound care providers. Some products are used in one surgery, such as sports medicine repair tools. Others are implants, such as knees and hips. Wound care includes dressings, pumps, and bioactive products used to help wounds heal.
The company reports three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. In 2025, those units generated $2,437 million, $1,934 million, and $1,793 million of revenue, respectively, based on the company annual report and full-year results.
This model breaks when pricing falls faster than volume can rise, or when operational execution misses. China value-based procurement hurt joint repair but has now fully annualized. A new risk involves supply and authorization friction, seen recently in CATALYSTEM deployment delays and SANTYL prior authorizations.
Advanced Wound Management is exposed to near-term rule changes. CMS is changing payment for skin substitutes in physician office and mobile settings. If clinics use fewer products or switch to cheaper ones, the profit hit could track toward the upper end of the company projections.
Products that must carry RISE
EVOS Plating System
EVOS is a trauma plating system used to repair broken bones. It has been one of the key drivers in Core Trauma.
CORI robotic platform
CORI helps surgeons plan and perform joint replacement procedures. The installed base exceeds 1,000 units, supporting knee and hip growth.
LANDMARK knee system
LANDMARK is the coming knee system launch. The cementless version is expected in the second half of 2026 and is the key test for U.S. Knees.
TESSA spatial surgery
Recently approved by the FDA, TESSA is a spatial surgery platform that adds a new commercial catalyst for the Sports Medicine segment.
REGENETEN and TENDON SEAM
REGENETEN supports biological rotator cuff repair, while TENDON SEAM adds biomechanical repair following the Integrity Orthopaedics acquisition.
SANTYL
SANTYL is an established wound care product. It helps anchor the wound care franchise, though it recently faced increased prior authorization friction.
2025 revenue mix
The mix uses 2025 business unit revenue: Orthopaedics $2,437 million, Sports Medicine & ENT $1,934 million, and Advanced Wound Management $1,793 million. Orthopaedics is the largest unit, but the 2026 narrative focuses on U.S. Recon execution and wound care margins.
What could break the case
Skin substitute reset
High impact · High oddsCMS reimbursement changes affect skin substitutes used in physician office and mobile settings. The pricing cap is tracking toward the upper end of the $20 million to $40 million incremental profit headwind range in 2026.
Deployment and authorization friction
Medium impact · High oddsU.S. Hips suffered temporary weakness due to CATALYSTEM set deployment delays. At the same time, SANTYL is facing increased prior authorization friction, slowing wound care sales.
LANDMARK launch misses
High impact · Medium oddsU.S. Knees growth remains soft. The company is managing capital efficiency before launching LANDMARK in the second half. If surgeons do not adopt LANDMARK quickly, the U.S. Knees gap may stay open.
Tariffs shifting to 2027
Medium impact · Medium oddsThe expected $60 million tariff headwind for 2026 is now broadly neutral net of refunds. However, cash tariff impacts may simply shift to 2027, creating a delayed margin risk.
In one breath
What does Smith & Nephew actually sell?
It sells medical devices used in joint replacement, trauma repair, sports medicine, ENT, and wound care. Examples include knee and hip implants, CORI robotics, rotator cuff repair products, and wound dressings.
Why is LANDMARK important for Smith & Nephew?
LANDMARK is the next knee system and is expected to launch in the second half of 2026. It matters because U.S. Knees growth has been soft, and investors need proof that the new system can close the gap with the market.
What is the biggest 2026 risk?
The biggest near-term risks are the upper end of a $20 million to $40 million profit hit from skin substitute reimbursement, CATALYSTEM deployment delays, and SANTYL prior authorization friction. Tariffs were a major fear but are now broadly neutral for 2026 net of refunds.
Is China still the main problem?
China is less central than it was because Joint Repair pricing pressure has fully annualized and China is a smaller part of the sales base than before. New AET and ENT value-based procurement rounds still matter, but management says they are much less material.
